Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Deferred Taxes (2016 - 2017)

CytomX Therapeutics (CTMX) has disclosed Deferred Taxes for 3 consecutive years, with -$520000.0 as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Deferred Taxes changed N/A year-over-year to -$520000.0, compared with a TTM value of -$513000.0 through Dec 2017, down 8650.0%, and an annual FY2017 reading of -$513000.0, down 8650.0% over the prior year.
  • Deferred Taxes was -$520000.0 for Q4 2017 at CytomX Therapeutics, down from -$19000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $25000.0 in Q2 2017 and bottomed at -$520000.0 in Q4 2017.
  • Average Deferred Taxes over 3 years is -$72000.0, with a median of $3000.0 recorded in 2015.
  • Peak annual rise in Deferred Taxes hit 733.33% in 2017, while the deepest fall reached 66.67% in 2017.
  • Year by year, Deferred Taxes stood at $3000.0 in 2015, then changed by 0.0% to $3000.0 in 2016, then crashed by 17433.33% to -$520000.0 in 2017.
  • Business Quant data shows Deferred Taxes for CTMX at -$520000.0 in Q4 2017, -$19000.0 in Q3 2017, and $25000.0 in Q2 2017.